Mechanisms of resistance to sotorasib in lung cancer identified

Oncology
–

First approved inhibitor once morest the KRAS oncogene.

Tumor cells rapidly adapt to the drug by increasing the number of copies of the mutated KRAS targeted by therapy.

Sotorasib-resistant lung cancer cells carrying multiple copies of the mutated KRAS gene (in red). Photo: CICANCER.